Logo image of PHXM

PHAXIAM Therapeutics SA (PHXM) Stock Fundamental Analysis

USA - NASDAQ:PHXM - US29604W2070 - ADR

3.1 USD
-0.02 (-0.64%)
Last: 3/8/2024, 8:27:22 PM
3.1 USD
0 (0%)
After Hours: 3/8/2024, 8:27:22 PM
Fundamental Rating

2

Overall PHXM gets a fundamental rating of 2 out of 10. We evaluated PHXM against 533 industry peers in the Biotechnology industry. PHXM may be in some trouble as it scores bad on both profitability and health. PHXM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

PHXM had negative earnings in the past year.
PHXM had a negative operating cash flow in the past year.
PHXM Yearly Net Income VS EBIT VS OCF VS FCFPHXM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -20M -40M -60M

1.2 Ratios

The Return On Assets of PHXM (-0.35%) is better than 93.60% of its industry peers.
With an excellent Return On Equity value of -0.62%, PHXM belongs to the best of the industry, outperforming 93.94% of the companies in the same industry.
Industry RankSector Rank
ROA -0.35%
ROE -0.62%
ROIC N/A
ROA(3y)-57.41%
ROA(5y)N/A
ROE(3y)-170.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PHXM Yearly ROA, ROE, ROICPHXM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

PHXM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHXM Yearly Profit, Operating, Gross MarginsPHXM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

PHXM does not have a ROIC to compare to the WACC, probably because it is not profitable.
PHXM has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for PHXM has been reduced compared to a year ago.
PHXM Yearly Shares OutstandingPHXM Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 1M 2M 3M 4M 5M
PHXM Yearly Total Debt VS Total AssetsPHXM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

PHXM has an Altman-Z score of -1.09. This is a bad value and indicates that PHXM is not financially healthy and even has some risk of bankruptcy.
PHXM has a Altman-Z score (-1.09) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.30 indicates that PHXM is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.30, PHXM is doing worse than 71.89% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z -1.09
ROIC/WACCN/A
WACC4.88%
PHXM Yearly LT Debt VS Equity VS FCFPHXM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 20M -20M -40M

2.3 Liquidity

PHXM has a Current Ratio of 1.78. This is a normal value and indicates that PHXM is financially healthy and should not expect problems in meeting its short term obligations.
PHXM has a Current ratio of 1.78. This is amonst the worse of the industry: PHXM underperforms 80.13% of its industry peers.
A Quick Ratio of 1.78 indicates that PHXM should not have too much problems paying its short term obligations.
PHXM has a worse Quick ratio (1.78) than 78.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78
PHXM Yearly Current Assets VS Current LiabilitesPHXM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

PHXM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.68%, which is quite impressive.
PHXM shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.04%.
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1025.16%
Revenue 1Y (TTM)59.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-70.86%

3.2 Future

Based on estimates for the next years, PHXM will show a very strong growth in Earnings Per Share. The EPS will grow by 23.84% on average per year.
PHXM is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.92% yearly.
EPS Next Y77.73%
EPS Next 2Y36.72%
EPS Next 3Y23.84%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%

3.3 Evolution

PHXM Yearly Revenue VS EstimatesPHXM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
PHXM Yearly EPS VS EstimatesPHXM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PHXM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PHXM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHXM Price Earnings VS Forward Price EarningsPHXM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHXM Per share dataPHXM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as PHXM's earnings are expected to grow with 23.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.72%
EPS Next 3Y23.84%

More info and screens

0

5. Dividend

5.1 Amount

PHXM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHAXIAM Therapeutics SA

NASDAQ:PHXM (3/8/2024, 8:27:22 PM)

After market: 3.1 0 (0%)

3.1

-0.02 (-0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)03-20 2024-03-20/amc
Inst Owners0.01%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.83M
Revenue(TTM)6.65M
Net Income(TTM)-228.00K
Analysts85
Price Target10.17 (228.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.8%
PT rev (3m)6.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-15.5%
EPS NY rev (3m)-0.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.6
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 2.87
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-4.14
FCFYN/A
OCF(TTM)-4.12
OCFYN/A
SpS1.19
BVpS6.57
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.35%
ROE -0.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.41%
ROA(5y)N/A
ROE(3y)-170.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.21%
Cap/Sales 1.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -1.09
F-Score3
WACC4.88%
ROIC/WACCN/A
Cap/Depr(3y)10.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.01%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1025.16%
EPS Next Y77.73%
EPS Next 2Y36.72%
EPS Next 3Y23.84%
EPS Next 5YN/A
Revenue 1Y (TTM)59.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-70.86%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
EBIT growth 1Y51.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.84%
EBIT Next 3Y11.18%
EBIT Next 5YN/A
FCF growth 1Y44.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.05%
OCF growth 3YN/A
OCF growth 5YN/A

PHAXIAM Therapeutics SA / PHXM FAQ

What is the fundamental rating for PHXM stock?

ChartMill assigns a fundamental rating of 2 / 10 to PHXM.


What is the valuation status for PHXM stock?

ChartMill assigns a valuation rating of 1 / 10 to PHAXIAM Therapeutics SA (PHXM). This can be considered as Overvalued.


What is the profitability of PHXM stock?

PHAXIAM Therapeutics SA (PHXM) has a profitability rating of 2 / 10.


How financially healthy is PHAXIAM Therapeutics SA?

The financial health rating of PHAXIAM Therapeutics SA (PHXM) is 2 / 10.